新型冠狀病毒

UAE to produce China’s Sinopharm Covid vaccine

Julphar deal with G42 will allow Gulf state to accelerate global supply plan

The United Arab Emirates will start producing the Chinese Sinopharm Covid-19 vaccine from April, helping the Gulf state accelerate plans to supply coronavirus jabs around the world.

Gulf Pharmaceutical Industries, also known as Julphar, said on Sunday it had signed a contract with Abu Dhabi’s G42 to produce the vaccine, which was trialled in the UAE and has since driven the country’s successful vaccination campaign.

The UAE, which began administering the jab to healthcare professionals last September, became the first country to approve Sinopharm for general use in December, saying it was 86 per cent effective in preventing Covid-19.

您已閱讀22%(639字),剩餘78%(2330字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×